Topic:

R&D

Latest Headlines

Latest Headlines

In a medical first, three patients receive prosthetic hands in place of disabled ones

Imagine having your disabled hand replaced with a functional prosthetic one. It's a reality, The Lancet pronounced, at least for three Austrian men who suffered from injuries to the network of nerves that originate in the neck and control movement from the shoulder down to the hand.

U.K. readies dementia R&D investment fund

Few could fault the United Kingdom for aiming too low. Having seen its CNS R&D chops whittled away by Big Pharma cuts, the U.K. government has decided the best way out of the mire is to take aim at one of the trickiest fields of all with a multimillion-pound dementia R&D investment fund.

Takeda's betting on its pipeline to spur a long-awaited turnaround

Japanese giant Takeda Pharmaceutical is planning to finally return to growth next year, counting on its late-stage medicines to the lead charge.

AstraZeneca bets $122.5M on oral autoimmune drugs

AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.

MIT team injects drug-carrying hydrogel that 're-heals' in the body

A team of MIT scientists has designed a new injectable hydrogel made from nanoparticles that could someday be used to hold drugs in the body, treating diseases such as cancer, macular degeneration and heart disease.

Exclusive: Pfizer is once again cutting back R&D staff in reorganization

Pfizer is once again trimming its R&D staff. Responding to a query from FierceBiotech regarding word of cutbacks at research facilities in Cambridge, MA, and Collegeville, PA, Pfizer spokesman Dean Mastrojohn sent back a confirmation, later declining to specify just how many jobs are being cut.

OncoSec's intratumoral delivery platform to be tested on new partner's cancer candidates

Oncology company Heat Biologics is partnering with OncoSec, developer of the ImmunoPulse intratumoral DNA delivery platform. The two companies will evaluate the combination of the immunotherapy approaches developed by each company, according to the release.

With Baxter split looming, biotech Baxalta finds a new home for corporate HQ

Baxter's big biotech spinoff Baxalta has found a corporate home. The company has leased a sprawling 260,000-square-foot facility in Bannockburn, IL, not far from its original HQ in northern Illinois.

Biotronik's investigational nitinol stent shows promise in clinical trials

Biotronik said at the Cardiovascular Research Technologies conference that its investigational Astron self-expanding nitinol stent for the narrowing of the leg's iliac or external arteries met its clinical endpoint, as the company chases FDA approval.

UPDATED: FDA agrees to review Endo Pharmaceutical's inside-the-cheek pain drug

Endo Pharmaceutical's investigational Belbuca buccal film strip for severe chronic pain has been accepted for review by the FDA, marking a win for the BioErodible MucoAdhesive technology to deliver drugs across mucosal surfaces like the inside of the cheek. And BEMA platform developer BioDelivery Sciences receives a $10 million milestone payment.